Get the latest Science News and Discoveries

New chelating agent reduces toxicity in PSMA radiopharmaceutical therapy - EurekAlert


A newly developed chelator can significantly reduce off-target toxicity in prostate-specific membrane antigen (PSMA) radiopharmaceutical therapy, according to research presented at the 2024 Society of Nuclear Medicine and Molecular Imaging Annual Meeting. By improving the bond between the radioactive metal ion and the PSMA-targeting antibody, the chelator can make PSMA therapy safer and more effective for patients.

None

Get the Android app

Or read this on Eureka Alert

Read more on:

Photo of New chelating agent

New chelating agent

Photo of toxicity

toxicity

Photo of EurekAlert

EurekAlert

Related news:

News photo

Pennington Biomedical Research Center recruiting participants for lipedema research study - EurekAlert

News photo

American College of Lifestyle Medicine announces induction into the American Medical Association House of Delegates - EurekAlert

News photo

States declare May 17 as NEC Awareness Day - EurekAlert